Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
MWN-AI** Summary
Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, has announced plans to present vital updates on its lead candidate, IMA203 TCR T-cell therapy, at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The event will take place from May 30 to June 3, 2025, in Chicago, Illinois.
The presentations will showcase updated findings from the Phase 1b trial of IMA203, which targets the PRAME antigen in patients with metastatic melanoma. This updated data will reflect a longer follow-up period since the last report in October 2024 and will also include results from additional patients with uveal melanoma. The presentation will be made by Dr. Martin Wermke and is scheduled for May 31, 2025.
In addition, a trial-in-progress poster will detail the SUPRAME Phase 3 clinical trial, currently evaluating IMA203 in patients with advanced cutaneous melanoma who have previously undergone PD-1 inhibitor treatment. This poster will be presented by Dr. Jason Luke on June 2, 2025.
IMA203 is an engineered T-cell receptor therapy noted for its precise targeting of PRAME, a protein associated with various solid tumors, while sparing healthy tissues. This therapy has shown promise in treating patients with significant unmet medical needs, evidenced by ongoing registration-enabling trials.
Immatics is committed to advancing cancer treatment through innovative therapies, combining target discovery with the development of effective T-cell receptors. The company aims to provide robust treatment options for patients facing challenging cancer diagnoses and emphasizes its ongoing engagement with stakeholders through various communication channels. For further details, Immatics encourages visiting their website and following their social media for updates.
MWN-AI** Analysis
Immatics N.V. (NASDAQ: IMTX) has generated investor interest with its upcoming presentations at the 2025 ASCO Annual Meeting, particularly regarding its lead product candidate, IMA203 TCR T-cell therapy targeting PRAME. The oral and poster presentations scheduled for late May and early June 2025 will provide updated insights into the performance of IMA203, particularly in the context of metastatic melanoma patients who are PD-1 refractory.
From a market perspective, the detailed information expected from the Phase 1b trial, featuring substantially longer follow-up data, is crucial. Investors should closely monitor these results as they could dramatically influence market sentiment toward Immatics. Positive outcomes could lead to increased investor confidence and potential upward pressure on the stock price, while disappointing results may have the opposite effect.
The SUPRAME Phase 3 trial's data presentation will also be critical in evaluating the therapeutic’s competitive positioning. IMA203's targeting mechanism against PRAME, a protein associated with multiple solid tumors, highlights its innovative approach in the increasingly competitive immunotherapy landscape. If the results verify its efficacy, it could bolster adoption rates among oncologists, driving higher revenue projections.
To capitalize on this upcoming data release, investors may consider adopting a cautious yet optimistic stance, utilizing both fundamental analysis of Immatics' pipeline and comparative assessment against competitor therapies. It is prudent to keep abreast of broader market trends in the oncology sector, including potential shifts in regulatory environments and competitive advancements.
In summary, while the forthcoming ASCO presentations could serve as significant catalysts for Immatics, investors should remain vigilant, evaluating both the immediate data and the long-term strategic positioning of IMA203 within the cancer therapy market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago, Illinois.
Updated data from the Phase 1b trial of IMA203 in patients with metastatic melanoma with substantially longer follow-up compared to the last presentation in October 2024, and including data from additional uveal melanoma patients enrolled since then, will be highlighted in an oral presentation.
In addition, a trial-in-progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have received prior treatment with a checkpoint inhibitor, will be presented at the conference.
Full abstracts will be available on the ASCO website on May 22, 2025, at 5:00 pm ET.
Oral Presentation
Title: Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma
Presenting author: Martin Wermke, MD
Session: Developmental Therapeutics – Immunotherapy
Date / Time: May 31, 2025 / 3:00 – 6:00 pm CDT
Abstract ID: 2508
Poster Presentation
Title: SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR T) vs investigator’s choice in patients with previously treated advanced cutaneous melanoma
Presenting author: Jason Luke, MD, FACP, FASCO
Session: Developmental Therapeutics - Immunotherapy
Date / Time: June 2, 2025 / 1:30 - 4:30 pm CDT
Abstract ID: TPS2673
About IMA203 TCR T-cell Therapy and Target PRAME
IMA203 is an autologous, engineered T-cell receptor T-cell therapy (TCR T) that targets PRAME, an intracellular protein displayed as a peptide antigen on the surface of multiple solid tumors via HLA-A*02:01, with minimal expression on healthy tissues. With precise targeting and a turnaround time of approximately 14 days, IMA203 has demonstrated a favorable clinical profile in patients with unmet medical needs.
IMA203 TCR T-cell therapy is currently being evaluated in a registration-enabling randomized controlled Phase 3 trial, “SUPRAME,” in patients with unresectable or metastatic cutaneous melanoma who have disease progression on or after at least one PD-1 inhibitor. In parallel, the Phase 1b clinical trial in patients with solid tumors expressing PRAME is ongoing with a focus on uveal melanoma.
About Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T-cell receptors with the goal of enabling a robust and specific T-cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates you can also follow us on Instagram and LinkedIn .
For more information, please contact:
Media
Trophic Communications
Phone: +49 151 74416179
immatics@trophic.eu
Immatics N.V.
Jordan Silverstein
Head of Strategy
Phone: +1 346 319-3325
InvestorRelations@immatics.com
Attachment
FAQ**
How does the investment climate in Houston, Texas compare to that in Tuebingen, Germany, specifically regarding biopharmaceutical companies like Immatics N.V. (IMTX)?
What impact might the upcoming ASCO presentations on Immatics N.V. (IMTX) have on investor interest in Houston versus Tuebingen?
Given the advancements in therapies like IMA203 by Immatics N.V. (IMTX), how might market trends in Houston and Tuebingen evolve in April 2025?
How are local regulatory environments in Houston, Texas, and Tuebingen, Germany, likely to influence the development and commercialization of Immatics N.V. (IMTX) therapies?
**MWN-AI FAQ is based on asking OpenAI questions about Immatics N.V. (NASDAQ: IMTX).
NASDAQ: IMTX
IMTX Trading
-0.61% G/L:
$11.37 Last:
87,110 Volume:
$11.48 Open:
